Traders Purchase High Volume of Precigen Call Options (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Investors acquired 11,343 call options on the stock. This is an increase of 3,908% compared to the average volume of 283 call options.

Institutional Trading of Precigen

Several institutional investors and hedge funds have recently made changes to their positions in the company. ClariVest Asset Management LLC boosted its stake in Precigen by 2.9% during the 2nd quarter. ClariVest Asset Management LLC now owns 492,152 shares of the biotechnology company's stock worth $778,000 after purchasing an additional 13,752 shares during the period. SG Americas Securities LLC raised its holdings in shares of Precigen by 44.2% in the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company's stock valued at $43,000 after buying an additional 13,823 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Precigen by 10.2% during the third quarter. Exchange Traded Concepts LLC now owns 167,496 shares of the biotechnology company's stock worth $159,000 after buying an additional 15,525 shares during the period. Stifel Financial Corp grew its holdings in shares of Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock worth $30,000 after buying an additional 15,680 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in Precigen by 40.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company's stock valued at $90,000 after acquiring an additional 16,486 shares during the period. 33.51% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and issued a $4.00 price objective on shares of Precigen in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $7.00.

Precigen Trading Down 3.6 %

Shares of NASDAQ PGEN traded down $0.04 during mid-day trading on Thursday, reaching $1.08. The company had a trading volume of 6,238,417 shares, compared to its average volume of 1,008,707. Precigen has a 52-week low of $0.65 and a 52-week high of $1.93. The stock has a market cap of $316.30 million, a P/E ratio of -1.96 and a beta of 1.71. The firm has a 50 day simple moving average of $0.84 and a two-hundred day simple moving average of $1.10.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.